Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance.

Holland WL, Brozinick JT, Wang LP, Hawkins ED, Sargent KM, Liu Y, Narra K, Hoehn KL, Knotts TA, Siesky A, Nelson DH, Karathanasis SK, Fontenot GK, Birnbaum MJ, Summers SA.

Cell Metab. 2007 Mar;5(3):167-79.

2.

Ceramides in insulin resistance and lipotoxicity.

Summers SA.

Prog Lipid Res. 2006 Jan;45(1):42-72. Epub 2005 Dec 19. Review.

PMID:
16445986
3.

Sphingolipids and insulin resistance: the five Ws.

Summers SA.

Curr Opin Lipidol. 2010 Apr;21(2):128-35. doi: 10.1097/MOL.0b013e3283373b66. Review.

PMID:
20216312
4.

Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism.

Holland WL, Summers SA.

Endocr Rev. 2008 Jun;29(4):381-402. doi: 10.1210/er.2007-0025. Epub 2008 May 1. Review.

5.
6.

Adipose tissue and ceramide biosynthesis in the pathogenesis of obesity.

Samad F, Badeanlou L, Shah C, Yang G.

Adv Exp Med Biol. 2011;721:67-86. doi: 10.1007/978-1-4614-0650-1_5. Review.

PMID:
21910083
7.

Understanding insulin resistance. What are the clinical implications?

Sivitz WI.

Postgrad Med. 2004 Jul;116(1):41-8. Review.

PMID:
15274287
8.

Sphingolipids: players in the pathology of metabolic disease.

Cowart LA.

Trends Endocrinol Metab. 2009 Jan;20(1):34-42. doi: 10.1016/j.tem.2008.09.004. Epub 2008 Nov 13. Review.

PMID:
19008117
9.

Sphingolipid targets in cancer therapy.

Modrak DE, Gold DV, Goldenberg DM.

Mol Cancer Ther. 2006 Feb;5(2):200-8. Review.

10.

Targeting ceramide metabolism in obesity.

Aburasayn H, Al Batran R, Ussher JR.

Am J Physiol Endocrinol Metab. 2016 Aug 1;311(2):E423-35. doi: 10.1152/ajpendo.00133.2016. Epub 2016 Jul 5. Review.

11.

Sphingolipids: agents provocateurs in the pathogenesis of insulin resistance.

Lipina C, Hundal HS.

Diabetologia. 2011 Jul;54(7):1596-607. doi: 10.1007/s00125-011-2127-3. Epub 2011 Apr 6. Review. Erratum in: Diabetologia. 2011 Nov;54(11):2969.

PMID:
21468641
12.

Glucocorticoids and insulin resistance: old hormones, new targets.

Andrews RC, Walker BR.

Clin Sci (Lond). 1999 May;96(5):513-23. Review.

PMID:
10209084
13.

Myocardial metabolism and cardiac performance in obesity and insulin resistance.

Banerjee S, Peterson LR.

Curr Cardiol Rep. 2007 Apr;9(2):143-9. Review.

PMID:
17430682
14.

Targeting sphingolipid metabolism in the treatment of obesity/type 2 diabetes.

Bellini L, Campana M, Mahfouz R, Carlier A, Véret J, Magnan C, Hajduch E, Le Stunff H.

Expert Opin Ther Targets. 2015;19(8):1037-50. doi: 10.1517/14728222.2015.1028359. Epub 2015 Mar 26. Review.

PMID:
25814122
15.

Effect of the dietary fat quality on insulin sensitivity.

Galgani JE, Uauy RD, Aguirre CA, Díaz EO.

Br J Nutr. 2008 Sep;100(3):471-9. doi: 10.1017/S0007114508894408. Epub 2008 Apr 8. Review.

PMID:
18394213
16.

Ceramides as modulators of cellular and whole-body metabolism.

Bikman BT, Summers SA.

J Clin Invest. 2011 Nov;121(11):4222-30. doi: 10.1172/JCI57144. Epub 2011 Nov 1. Review.

17.

Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.

Resmini E, Minuto F, Colao A, Ferone D.

Acta Diabetol. 2009 Jun;46(2):85-95. doi: 10.1007/s00592-009-0112-9. Epub 2009 Mar 26. Review.

PMID:
19322513
18.

Mechanisms of lipoapoptosis: implications for human heart disease.

Listenberger LL, Schaffer JE.

Trends Cardiovasc Med. 2002 Apr;12(3):134-8. Review.

PMID:
12007739
19.

The twists and turns of sphingolipid pathway in glucose regulation.

Deevska GM, Nikolova-Karakashian MN.

Biochimie. 2011 Jan;93(1):32-8. doi: 10.1016/j.biochi.2010.05.016. Epub 2010 May 31. Review.

20.

Ceramides - Lipotoxic Inducers of Metabolic Disorders.

Chaurasia B, Summers SA.

Trends Endocrinol Metab. 2015 Oct;26(10):538-50. doi: 10.1016/j.tem.2015.07.006. Review.

PMID:
26412155

Supplemental Content

Support Center